3-Aminopperidine-2,6-Dion Hydrochloride CAS 24666-56-6;2686-86-4 daahirnimo>99.0% Warshada dhexe ee Lenalidomide
Kiimikada Ruifu waa soo saaraha ugu horreeya ee 3-Aminopperidine-2,6-Dion Hydrochloride (CAS: 24666-56-6; 2686-86-4) oo leh tayo sare, dhexdhexaad ah Pomalidomide (CAS: 19171-19-8).Kiimikada Ruifu waxay bixin kartaa gaarsiinta adduunka oo dhan, qiimo tartan ah, adeeg aad u wanaagsan, tiro yar iyo tiro badan oo la heli karo.Iibso 3-Aminopperidine-2,6-Dion Hydrochloride, Please contact: alvin@ruifuchem.com
| Magaca Kiimikada | 3-Aminopperidine-2,6-Dion Hydrochloride |
| La mid ah | 3-Aminopperidine-2,6-Dione HCl;3-Amino-2,6-Piperidinedione Hydrochloride;2,6-Dioxopiperidine-3-Ammonium Chloride |
| Lambarka CAS | 24666-56-6 |
| CAS la xidhiidha | 2686-86-4;25181-50-4 |
| Heerka Saamiyada | Kaydka dhexdiisa, Qiyaasta Waxsoosaarka Ilaa Tan |
| Qaanuunka molecular | C5H9ClN2O2 |
| Miisaanka Molecular | 164.59 |
| Meesha dhalaalaysa | 120℃ |
| COA & MSDS | La heli karo |
| Asal ahaan | Shanghai, Shiinaha |
| Summada | Kiimikada Ruifu |
| Shayga | Tilmaamaha |
| Muuqashada | Budada Crystalline Off-White |
| Daahirnimada / Habka Falanqaynta | >99.0% (HPLC) |
| Qoyaanka (KF) | <0.50% |
| Khasaare xagga qalajinta | <0.50% |
| Hadhaaga dabka | <0.20% |
| Wadarta wasakhda | <1.00% |
| Infrared Spectrum | Waafaqsan Qaab-dhismeedka |
| Heerka Imtixaanka | Heerka Ganacsiga |
| Isticmaalka | Dhexdhexaadka Lenalidomide (CAS: 191732-72-6) |
Xidhmada: Dhalo, bacda bireed aluminium, 25kg / Durbaan kartoonada, ama sida waafaqsan shuruudaha macmiilka
Xaaladda Kaydinta:Ku kaydi weelasha xiran meel qabow oo qallalan;Ka ilaali iftiinka iyo qoyaanka
3-Aminopperidine-2,6-Dione Hydrochloride (CAS: 24666-56-6; 2686-86-4) waa dhexdhexaadiyaha diyaarinta Lenalidomide (CAS: 191732-72-6).Lenalidomide waa nooc ka mid ah dawooyinka ka hortagga tumor-ka ee ay soo saareen shirkadaha dawooyinka bayoolajiga Maraykanka.Waxay leedahay hawlo badan sida burooyinka ka hortagga, xakamaynta difaaca iyo anti-angiogenesis.Waxay joojin kartaa dheecaanka cytokines bararka, waxayna kordhisaa dheecaanka xuubka dhiigga ee mononuclear anti-inflammatory cytokines.Waxay joojin kartaa korriinka unugyada myeloma badan ee bukaanka iyo unugga MM1S.Laba-indho-indho-indho-indho-indho-indho-indho-indho-indho-baaris caafimaad oo la xakameeyey oo laba xarumood badan leh ayaa qiimeeya badbaadada iyo saameynta daaweynta lenalidomide ee loo isticmaalo myeloma badan.Natiijooyinka cilmi-baaris caafimaad ee ugu dambeeyay waxay muujinayaan in lenalidomide aysan kaliya saameyn daaweyn ah ku yeelanin daaweynta MDS iyo MM, laakiin sidoo kale daaweynta myeloma, leukemia, kansarka kelyaha ee metastatic, burada adag, amyloidosis guud ee idiopathic iyo cudurka fibrosis ee dhuuxa nidaamka leh ee dhuuxa aan bislaan.Bishii Disembar 2005, Maamulka Cuntada iyo Dawooyinka ee Mareykanka (FDA) ayaa oggolaaday lenalidomide in loo isticmaalo daawaynta cudurka myelodysplastic syndrome (MDS).
